Literature DB >> 18205037

The effect of oral contraceptive pill for cycle scheduling prior to GnRH-antagonist protocol on IVF cycle parameters and pregnancy outcome.

Haim Pinkas1, Onit Sapir, Ori M Avrech, Avi Ben-Haroush, Jacob Ashkenzi, Benjamin Fisch, Jacob Farhi.   

Abstract

OBJECTIVE: To evaluate the effect of oral contraceptive pills (OCP) pretreatment on IVF cycle outcome in GnRH-antagonist protocol.
DESIGN: Retrospective cohort study.
SETTING: Major tertiary university-affiliated center. PATIENTS: All patients treated with GnRH antagonist in our IVF unit during the last 3 years were included in the study. Overall 1,799 IVF cycles were performed. Of these, in 604 cycles OCP pretreatment was used prior to GnRH-antagonist for cycle scheduling. Patients were divided into two age groups-young group aged < or = 35 years and older group aged > or = 36 years.
INTERVENTIONS: The young group underwent 927 cycles, 281 cycles with OCP pretreatment and 646 cycles without. The older group underwent 872 cycles, 323 cycles with OCP pretreatment and 549 cycles without. Data was analyzed within each age group. MAIN OUTCOME MEASURES: Treatment duration and total dose of FSH IU used for stimulation, number of oocytes retrieved, implantation and pregnancy rates.
RESULTS: All OCP-pretreated cycles required significantly longer stimulation than non-pretreated cycles (young: 10.76 vs. 9.21 days; older: 10.48 vs. 8.73 days, respectively) and higher total dose of FSH IU (young: 3,210 IU vs. 2,565 IU; older: 4,973 IU vs. 3,983 IU, respectively). There were no other differences in cycle characteristics between groups. Implantation and pregnancy rates were not affected by OCP pretreatment.
CONCLUSIONS: OCP pretreatment can be offered as a mode for cycle scheduling prior to GnRH-antagonist protocol, though it may be associated with longer stimulation and higher gonadotropin consumption.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18205037      PMCID: PMC2582103          DOI: 10.1007/s10815-007-9189-7

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  8 in total

1.  Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study.

Authors:  Judith A F Huirne; Andre C D van Loenen; Jacques Donnez; Céline Pirard; Roy Homburg; Roel Schats; Joseph McDonnell; Cornelis B Lambalk
Journal:  Reprod Biomed Online       Date:  2006-08       Impact factor: 3.828

2.  Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.

Authors:  C Albano; R E Felberbaum; J Smitz; H Riethmüller-Winzen; J Engel; K Diedrich; P Devroey
Journal:  Hum Reprod       Date:  2000-03       Impact factor: 6.918

3.  A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients.

Authors:  Luk Rombauts; David Healy; Rob J Norman
Journal:  Hum Reprod       Date:  2005-10-27       Impact factor: 6.918

4.  GnRH antagonist in assisted reproduction: a Cochrane review.

Authors:  Hesham Al-Inany; Mohamed Aboulghar
Journal:  Hum Reprod       Date:  2002-04       Impact factor: 6.918

5.  Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial.

Authors:  Efstratios M Kolibianakis; Evangelos G Papanikolaou; Michel Camus; Herman Tournaye; Andre C Van Steirteghem; Paul Devroey
Journal:  Hum Reprod       Date:  2005-11-03       Impact factor: 6.918

6.  A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.

Authors:  Larry I Barmat; Samuel J Chantilis; Bradley S Hurst; Richard P Dickey
Journal:  Fertil Steril       Date:  2005-02       Impact factor: 7.329

7.  Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study.

Authors:  I Cédrin-Durnerin; D Grange-Dujardin; A Laffy; I Parneix; N Massin; J Galey; L Théron; J P Wolf; C Conord; P Clément; S Jayot; J N Hugues
Journal:  Hum Reprod       Date:  2004-06-10       Impact factor: 6.918

8.  A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.

Authors:  Femke P Hohmann; Nicholas S Macklon; Bart C J M Fauser
Journal:  J Clin Endocrinol Metab       Date:  2003-01       Impact factor: 5.958

  8 in total
  4 in total

1.  Agonist depot versus OCP programming of frozen embryo transfer: a retrospective analysis of freeze-all cycles.

Authors:  Kemal Ozgur; Murat Berkkanoglu; Hasan Bulut; Peter Humaidan; Kevin Coetzee
Journal:  J Assist Reprod Genet       Date:  2015-12-23       Impact factor: 3.412

Review 2.  Challenges and considerations in optimizing ovarian stimulation protocols in oncofertility patients.

Authors:  Kathryn Coyne; MacKenzie Purdy; Kathleen O'Leary; Jerome L Yaklic; Steven R Lindheim; Leslie A Appiah
Journal:  Front Public Health       Date:  2014-12-05

3.  Consensus Statement on the Use of Oral Contraceptive Pills in Polycystic Ovarian Syndrome Women in India.

Authors:  Duru Shah; Madhuri Patil
Journal:  J Hum Reprod Sci       Date:  2018 Apr-Jun

Review 4.  Optimal usage of the GnRH antagonists: a review of the literature.

Authors:  Alan B Copperman; Claudio Benadiva
Journal:  Reprod Biol Endocrinol       Date:  2013-03-15       Impact factor: 5.211

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.